24/7 Market News Snapshot 27 January, 2025 – IMAC Holdings, Inc. Common Stock (NASDAQ:BACK)

January 27, 2025

DENVER, Colo., 27 January, 2025 (247marketnews.com) – (NASDAQ:BACK) are discussed in this article.
IMAC Holdings, Inc. is experiencing significant momentum in the market, with its stock price soaring by over 61.65% to trade at $1.188, following an opening price of $0.74. This impressive movement is accompanied by robust trading activity, evidenced by a volume of 2.23 million shares exchanged, reflecting strong investor enthusiasm and confidence in the company’s strategic direction.

In line with its growth trajectory, IMAC Holdings has announced the formation of Ignite Proteomics LLC, a new subsidiary focused on personalized cancer treatment. This innovative initiative addresses the urgent need for more effective approaches in tailoring therapies, specifically for challenging conditions like breast cancer. By capitalizing on advanced protein-level insights, Ignite Proteomics aims to enhance the current landscape of genomic testing, which, while widely used, has yet to fully leverage the potential for optimizing patient care.

Ignite’s multi-protein testing platform is designed to provide healthcare providers with comprehensive insights from a single sample, revealing crucial tumor characteristics that influence treatment responses. Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics, emphasized the platform’s significance, highlighting its capacity to facilitate better informed treatment decisions based on real-time protein signals.

Furthermore, Ignite’s offerings promise to identify drug targets that other methods may miss and evaluate the efficacy of immunotherapies, aiming to streamline the treatment selection process that typically involves extensive trial and error. As the initiative progresses, collaborations with leading cancer centers are underway to generate clinical evidence and integrate this advanced testing into routine care.

Through these pioneering efforts, IMAC Holdings, Inc. is poised to reshape cancer treatment protocols, enhancing patient outcomes by ushering in a new standard of care grounded in precision medicine.

Related news for (BACK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.